Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A; EORTC Melanoma Group.

Eur J Cancer. 2011 Jul;47(10):1476-83. doi: 10.1016/j.ejca.2011.04.030. Epub 2011 May 18.

PMID:
21600759
[PubMed - indexed for MEDLINE]
2.

Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome.

Bouwhuis MG, Collette S, Suciu S, de Groot ER, Kruit WH, Ten Hagen TL, Aarden LA, Eggermont AM, Swaak AJ; EORTC Melanoma Group.

Melanoma Res. 2011 Aug;21(4):344-51. doi: 10.1097/CMR.0b013e328346c17f.

PMID:
21546857
[PubMed - indexed for MEDLINE]
3.

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group.

J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. doi: 10.1093/jnci/djp132. Epub 2009 Jun 9.

PMID:
19509353
[PubMed - indexed for MEDLINE]
Free Article
4.

Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.

Kannengiesser C, Spatz A, Michiels S, Eychène A, Dessen P, Lazar V, Winnepenninckx V, Lesueur F, Druillennec S, Robert C, van den Oord JJ, Sarasin A, Bressac-de Paillerets B; EORTC Melanoma group.

Mol Oncol. 2008 Apr;1(4):425-30. doi: 10.1016/j.molonc.2008.01.002. Epub 2008 Jan 12.

PMID:
19383316
[PubMed - indexed for MEDLINE]
Free Article
5.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group.

Lancet. 2008 Jul 12;372(9633):117-26. doi: 10.1016/S0140-6736(08)61033-8.

PMID:
18620949
[PubMed - indexed for MEDLINE]
6.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group.

Lancet. 2005 Oct 1;366(9492):1189-96.

PMID:
16198768
[PubMed - indexed for MEDLINE]
7.

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.

Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG).

Eur J Cancer. 2004 Feb;40(3):390-402.

PMID:
14746858
[PubMed - indexed for MEDLINE]
8.

The development of optimal pathological assessment of sentinel lymph nodes for melanoma.

Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, Kissin MW, Powell BW; EORTC Melanoma Group.

J Pathol. 2003 Jul;200(3):314-9.

PMID:
12845627
[PubMed - indexed for MEDLINE]
9.

Pathologic staging of melanoma.

Ruiter DJ, Spatz A, van den Oord JJ, Cook MG; Pathology Committee of the European Organization Research and Treatment of Cancer (EORTC) Melanoma Group.

Semin Oncol. 2002 Aug;29(4):370-81. Review.

PMID:
12170440
[PubMed - indexed for MEDLINE]
10.

The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer.

Eggermont AM, Keilholz U, Autier P, Ruiter DJ, Lehmann F, Lienard D; EORTC Melanoma Group.

Eur J Cancer. 2002 Mar;38 Suppl 4:S114-9.

PMID:
11858976
[PubMed - indexed for MEDLINE]
11.

Microstaging in cutaneous melanoma.

Ruiter DJ, Spatz A, van den Oord JJ, Cook MG; Pathology Committee of the EORTC Melanoma Group.

J Pathol. 2001 Dec;195(5):525-9. Review.

PMID:
11745686
[PubMed - indexed for MEDLINE]
12.

On the release and half-life of S100B protein in the peripheral blood of melanoma patients.

Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F; EORTC Melanoma Group.

Int J Cancer. 2001 Nov;94(4):586-90.

PMID:
11745448
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk